Skip to Content

Calculating Drug Design

The pharmaceutical industry dreams of using computers to predict which potential drugs will work best and have the fewest side effects. Until recently, the software that performs such simulations has been slow, difficult for the average chemist to access and use, and worst of all, often inaccurate; but a collaboration between University of North Carolina at Chapel Hill computational chemist Alex Tropsha and IBM is making predictive drug screening easier and more accessible. Researchers who have encountered difficulty with a drug candidate can submit data on its structure and biological functionality to Tropsha’s program via a Linux-based Web portal designed by IBM. Running on a cluster of high-powered computers, Tropsha’s software screens a large database of compounds to help identify more-promising candidates. “Now, all a chemist who uses the program has to know is chemistry,” says Tropsha. The program has already singled out compounds that could help treat conditions such as convulsions and hemophilia, and Tropsha hopes to commercialize the software this year.

Keep Reading

Most Popular

The inside story of how ChatGPT was built from the people who made it

Exclusive conversations that take us behind the scenes of a cultural phenomenon.

How Rust went from a side project to the world’s most-loved programming language

For decades, coders wrote critical systems in C and C++. Now they turn to Rust.

Design thinking was supposed to fix the world. Where did it go wrong?

An approach that promised to democratize design may have done the opposite.

Sam Altman invested $180 million into a company trying to delay death

Can anti-aging breakthroughs add 10 healthy years to the human life span? The CEO of OpenAI is paying to find out.

Stay connected

Illustration by Rose Wong

Get the latest updates from
MIT Technology Review

Discover special offers, top stories, upcoming events, and more.

Thank you for submitting your email!

Explore more newsletters

It looks like something went wrong.

We’re having trouble saving your preferences. Try refreshing this page and updating them one more time. If you continue to get this message, reach out to us at customer-service@technologyreview.com with a list of newsletters you’d like to receive.